Erlonat Indications/Uses

Non-Small Cell Lung Cancer (NSCLC): Erlotinib tablets are indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor activating mutations (EGFR).
Erlotinib tablets are also indicated for the treatment of patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy.
Erlotinib tablets are also indicated for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. In patients with tumours without EGFR activating mutations, ERLONAT is indicated when other treatment options are not considered suitable.
When prescribing erlotinib tablets, factors associated with prolonged survival should be taken into account.
No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumours (see Pharmacology: Pharmacodynamics under Actions).
Pancreatic cancer: Erlotinib tablets in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer.
When prescribing erlotinib tablets, factors associated with prolonged survival should be taken into account (see Dosage & Administration and Pharmacology: Pharmacodynamics under Actions).
No survival advantage could be shown for patients with locally advanced disease.